NEW YORK (GenomeWeb News) – Molecular diagnostics developer DxS has received European Union approval to sell its TheraScreen K-RAS Mutation Kit for use on Roche's LightCycler 480 Instrument II.

DxS said that the CE-IVD Mark will enable the firm to sell the test, which is used to monitor patient response to Amgen's panitumumab (Vectibix) and Merck's cetuximab (Erbitux) drugs for colorectal cancer, in clinical settings in the EU.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.